A late-breaking ENDO 2026 analysis examined the relationship between lorundrostat and heart failure-associated biomarkers.
A proteomic analysis presented as late-breaking research at ENDO 2026 found that treatment with lorundrostat was associated with reductions in several circulating biomarkers linked to heart failure risk in patients with uncontrolled hypertension.
The post hoc analysis included samples from participants enrolled in the phase 3 Launch-HTN (NCT06153693) and phase 2 Advance-HTN (NCT05769608) studies. Investigators evaluated changes in circulating protein biomarkers after 12 weeks of treatment to explore the potential biological effects of aldosterone synthase inhibition on pathways implicated in heart failure pathophysiology.
Don’t miss out on hearing about our latest peer-reviewed articles, expert opinions, conference news, podcasts and more.
Changes in heart failure-associated biomarkers
Investigators observed changes in components of the renin–angiotensin–aldosterone system (RAAS), including increased renin and reduced angiotensinogen, findings consistent with target engagement.
Lorundrostat treatment was associated with placebo-adjusted reductions in several circulating biomarkers previously linked to incident heart failure, including NT-proBNP (−11.5%), MFAP4 (−18.1%), SVEP1 (−11.7%), NRP1 (−8.9%), and SPON1 (−4.0%).
Investigators also reported reductions in biomarkers linked to extracellular matrix remodeling and vascular activation, alongside increases in biomarkers involved in hemostasis and protease inhibitor activity. Furthermore, findings from a network analysis suggested that reductions in heart failure-associated biomarkers occurred alongside changes in a core extracellular matrix remodeling network.
Jon Congleton, Chief Executive Officer of Mineralys Therapeutics said: “Aldosterone plays a well-established role in driving this disease, and these findings suggest that lorundrostat may act on the biological processes that contribute to heart failure, supporting further evaluation of its therapeutic potential in this setting.”
Confirmatory studies will be required to determine whether these biomarker changes translate into clinical cardiovascular effects.
Regulatory context
The findings were presented during a late-breaking session at the Endocrine Society Annual Meeting (ENDO 2026), ahead of the anticipated US Food and Drug Administration (FDA) decision on lorundrostat for the treatment of uncontrolled hypertension.
While the current regulatory review is based on efficacy and safety data from the phase 3 clinical development program, these exploratory analyses provide additional insight into the potential biological effects of aldosterone synthase inhibition.
Abstract: SUN-257 – Lorundrostat Modulates Heart Failure Risk Biomarkers in Participants with Uncontrolled Hypertension. ENDO 2026, June 13-26 2026, Chicago, IL, USA.
This content has been developed independently by Touch Medical Media for touchCARDIO, utilizing AI as an editorial tool (ChatGPT (GPT-4o) [Large language model]. https://chat.openai.com/chat.) No funding was received in the publication of this article.
Cite: Could lorundrostat influence heart failure biology? New biomarker data presented at ENDO 2026. touchCARDIO. July 08 2026.
Editor: Victoria Smith, Senior Content Editor.
